The Influence of PRN Omega-3 Nutritional Supplement on Visual Acuity

The Influence of PRN Omega-3 Nutritional Supplement on Visual Acuity Outcomes In Cases Undergoing Cataract Surgery: A Pilot Study.

Status

UNKNOWN

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02260973

Enrollment

150

Registered

2014-10-09

Start date

2014-11-30

Completion date

2016-12-31

Last updated

2016-08-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cataract, Dry Eye Disease

Brief summary

This is a randomized, masked, placebo controlled study to assess the effect on visual acuity, if any, of the PRN omega-3 nutritional supplement in subjects undergoing cataract surgery.

Interventions

DIETARY_SUPPLEMENTOmega-3 (Triglyceride form)

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

SUPPORTIVE_CARE

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

30 Years to 90 Years

Healthy volunteers

Inclusion criteria

* Presence of nuclear or cortical lens opacities in one/both eyes * Physician diagnosis of age related cataract * Good overall physical constitution * All participants must be follow the same regimen for surgery related medications, both pre and post surgery. (Antibiotic, NSAID and Steroid eye drops)

Exclusion criteria

* Subjects requiring Premium IOLs/multifocal implants * Advanced cataract * Severe Age-Related Macular Degeneration Presence or history of Glaucoma * Presence or history of Diabetes Mellitus * Any Retinal pathology - retinal detachment, retinitis pigmentosa, diabetic retinopathy, etc * Vision loss due to Central retinal artery occlusion or Central retinal vein occlusion * Vision loss due to presence of large pituitary tumors or aneurysms * Vision loss due to optic tract lesions * Vision loss due to bleeding into aqueous or vitreous chamber * Vision loss due to drug toxicity: Amiodarone, anti-tuberculosis drugs, hydroxychloroquine, tamoxifen * Major cardiovascular or cerebral events in the past 12 months * Allergy to fish oil or safflower oil * Pregnancy or lactation at any time during the study * Newly started or increased the dose of chronic systemic medication known to affect tear production including, but not limited to antihistamines, antidepressants, diuretics, corticosteroids or immunomodulators within 30 days of Screening or at any time during the study * Participation in any other study involving an investigational drug or device within the past 30 days

Design outcomes

Primary

Measure	Time frame
Visual Acuity	8 weeks

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026